首页> 外文OA文献 >Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen

【2h】

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen

机译：异基因造血干细胞移植（HSCT），用于使用AML或MDS进行清髓，降低毒性的白消安/氟达拉滨（BuFlu）调理方案治疗6到7岁的AML或MDS患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Alatrash G.; Andersson B.; Pelosini M.; Rondon G.; Qazilbash M.; Giralt S.; de Padua Silva L.; Hosing C.; Kebriaei P.; Zhang W.; Saliba R.; Champlin R.; de Lima M.;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Is Busulfan and Fludarabine an Optimal Myeloablative Hematopoietic Stem Cell Transplant (HSCT) Conditioning Regimen in Children with AML/MDS ? [J] . Ramzan Mohammed, Ali Muhammad, Krueger Joerg, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：白消安和氟达拉滨是否是AML / MDS儿童的最佳清髓造血干细胞移植（HSCT）条件疗法？
2. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. [J] . Alatrash G, de Lima M, Hamerschlak N, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2011,第10期

机译：i.v.清髓毒性降低白消安-氟达拉滨和同种异体造血干细胞移植治疗急性髓性白血病或骨髓增生异常综合征的患者，年龄在第六至八十年。
3. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS [J] . De La Serna J., Sanz J., Bermudez A., Bone marrow transplantation . 2016,第7期

机译：白消安和氟达拉滨清髓条件对AML和MDS中HLA同胞同种异体造血细胞移植的毒性和功效
4. Intravenous Busulfan Reduces Toxicity Associated with Myeloablative Allogeneic Hematopoietic Transplantation in Patients with Myeloid Malignancies [C] . A. Shimoni, B. Bxelorai, I. Hardan, European Haematology Association . 2002

机译：静脉内的伯鲁兰减少骨髓恶性肿瘤患者患有髓鞘异产造血移植的毒性
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life [O] . Gheath Alatrash, Marcos de Lima, Nelson Hamerschlak, -1

机译：清髓性降低毒性IV白消安氟达拉滨和同种异体造血干细胞移植的患者通过第八十年的生活急性骨髓性白血病或骨髓增生异常综合征中的第六
7. Allogeneic Hematopoietic Stem Cell Transplantation (SCT) Using Fludarabine/Treosulfan Conditioning Regimen Compared With Busulfan-Based Myeloablative And Reduced-Intensity Conditioning In Patients With AML And MDS; Relative Outcomes Depend On Disease Status At SCT [O] . Shimoni A., Shem-Tov N., Rand A., 2010

机译：氟达拉滨/三硫磺调理方案的异基因造血干细胞移植与AML和MDS患者基于白消安的清髓和降低强度调理的比较；相对结果取决于SCT的疾病状况

Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen

著录项

引文网络

相似文献

相关主题

期刊订阅